What is the story about?
What's Happening?
MoldCo, a telehealth platform focused on diagnosing and treating mold-related illnesses, has successfully raised $8 million in seed funding. The funding round was co-led by Cantos and Collaborative Fund, increasing the company's total funding to $11 million. MoldCo aims to address the widespread issue of mold toxicity, which affects over 50% of U.S. households. Despite the prevalence of mold-related health issues, many physicians do not screen for or treat these conditions, leaving a significant gap in care. MoldCo's platform offers patients immediate access to evidence-based care, including virtual consultations, advanced lab testing, and treatments delivered to their homes. The service costs between $150 and $300 per month, significantly less than traditional alternatives. The company's founder, Ariana Thacker, developed MoldCo after experiencing challenges with conventional medicine while battling mold illness herself.
Why It's Important?
The funding and expansion of MoldCo's services are crucial in addressing the 'invisible health crisis' of mold toxicity in the U.S. Mold exposure can lead to serious long-term health issues, such as Chronic Inflammatory Response Syndrome (CIRS), often misdiagnosed as other conditions like chronic fatigue or fibromyalgia. By making specialized care more accessible and affordable, MoldCo is poised to fill a critical gap in healthcare. This development could lead to improved health outcomes for individuals suffering from mold-related illnesses and reduce the financial burden associated with seeking treatment. The expansion of MoldCo's network of clinicians and proprietary technology could also set a precedent for integrating telehealth solutions into routine care practices.
What's Next?
With the new funding, MoldCo plans to expand its network of specialized clinicians across the United States and develop its proprietary care technology further. The company is also investing in clinical research collaborations to standardize mold detox as a routine part of healthcare, akin to regular physical or dental exams. Currently, MoldCo offers advanced lab testing in 46 states and provides care in select states, with plans to be available nationwide by 2026. This expansion could lead to broader acceptance and integration of mold toxicity treatment in mainstream healthcare.
AI Generated Content
Do you find this article useful?
